November 2023

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed.     Enquiries:   Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand...

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government’s Advancing Precision Medicine programme.  The grant-funded project is called “PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool” (the...

Physiomics plc (AIM: PYC), is pleased to announce that, following today’s announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company’s personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT.   The presentation is open to all existing and potential...